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Manganese superoxide dismutase (SOD2) is an enzyme that catalyses the dismutation of superoxide in the mitochondria, leading to
reduced levels of reactive oxygen species. Reduced expression levels of SOD2 have been shown to result in increased DNA damage
and sod2 heterozygous mice have increased incidences of cancer. It has also been shown that SOD2 expression is lost in pancreatic
cell lines, with reintroduction of SOD2 resulting in decreased rate of proliferation. The mechanism of decreased SOD2 expression in
pancreatic carcinoma has not been previously determined. We demonstrate, through sodium bisulphite sequencing, that the sod2
locus is methylated in some pancreatic cell lines leading to a corresponding decrease in SOD2 expression. Methylation can be
reversed by treatment with zebularine, a methyltransferase inhibitor, resulting in restored SOD2 expression. Furthermore, we
demonstrate that sensitivity of pancreatic carcinoma cell lines to 2-methoxyestradiol correlates with SOD2 expression and SOD2
modulation can alter the sensitivity of these cells. Using both genomics and proteomics, we also identify molecular consequences of
SOD2 expression in MIA-PaCa2 cells, including dephosphorylation of VEGFR2 and the identification of both SOD2-regulated genes
and transcription factors with altered binding activity in response to SOD2 expression.
British Journal of Cancer (2007) 97, 1116–1123. doi:10.1038/sj.bjc.6604000 www.bjcancer.com
Published online 25 September 2007
& 2007 Cancer Research UK
Keywords: superoxide dismutase 2; pancreatic neoplasms; proteomics; genomics; epigenetic process
                                               
Free radicals are, arguably, considered among the most potent,
ubiquitous, endogenous mutagens generated by normal physiolo-
gical processes (Hussain et al, 2003). Among various molecular
forms of free radicals, reactive oxygen species (ROS) have been the
most diligently studied. Generated by all cells as a by-product of
oxidative metabolism and inflammatory processes, ROS are
indicted in inducing cellular aging (Melov, 2000), cancer, and a
variety of other pathophysiological conditions. Alterations in
macromolecular functions are understandable in view that ROS
may target DNA, proteins, RNA, and lipids. Due to the deleterious
potential of free radicals, mechanisms have evolved to protect cells
from ROS, including antioxidant scavengers, enzymes, and repair
mechanisms.
Cancer, in particular, arises from a combination of potential
genetic mutations, and possibly epigenetic changes, altering the
cells’ normal proliferative and apoptotic programming. Within the
last few years, changes in expression patterns of enzymes that
stand as guardians for ROS have been implicated in the possible
progression or initiation of some cancers. Considered among the
earliest pre-neoplastic changes in prostate cancer is the epigenetic
silencing by promoter CpG hypermethylation of the glutathione
S-transferase p gene (Lin et al, 2001; Nelson et al, 2001). Thus,
speculating that a reduction in the ability to manage ROS leads to
further mutation and advancement of the neoplastic process.
Among the enzymes produced by cells that manage ROS,
manganese superoxide dismutase (SOD2), the form of SOD found
in mitochondria, has received considerable attention with regard
to cancer (Liu et al, 2004). The main function of SOD2 is to convert
superoxide anion into hydrogen peroxide (H2O2), which is
subsequently converted to water by catalases. Decreased expres-
sion of SOD2 has been noted, initially, in pancreatic carcinoma
cells lines (Cullen et al, 2003). More recently, reduced expression
of SOD2 has been seen in multiple myeloma cells (Hodge et al,
2005b), androgen-independent prostate cancer (Best et al, 2005;
Venkataraman et al, 2005), and invasive breast carcinoma (Soini
et al, 2001). Overexpression of SOD2 in deficient cell lines has
reduced the proliferation of pancreatic carcinoma cells (Weydert
et al, 2003; Ough et al, 2004), multiple myeloma cells (Hodge et al,
2005b), glioma cells (Zhong et al, 1997), squamous oral carcinoma
cells (Liu et al, 1997), and prostate carcinoma cells (Li et al, 1998b;
Zhong et al, 2004; Venkataraman et al, 2005). Transgenic
overexpression of SOD2 also results in increased resistance to
chemical carcinogenesis as compared to wild-type mice (Zhao
et al, 2001). While homozygous sod2 knockout mice die within
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sweeks, heterozygous þ/  mice have accelerated tumour
development, particularly lymphomas (Van Remmen et al, 2003).
Taken together, these data have raised the compelling issue that, in
addition to the effects of SOD2 as a guardian against ROS, SOD2
may phenotypically act as a tumour suppressor (Cullen et al,
2003).
While the phenotypic effects of diminished and/or over-
expressed SOD2 have been reported for various tumour cell lines,
the explanation for reduced expression has only recently emerged.
Polymorphisms of the sod2 promoter have been suggested as one
possible mechanism for reduced expression of SOD2 in certain cell
lines (Xu et al, 1999). More recently, we have found that the sod2
promoter is methylated in some multiple myeloma cells and
diminished expression can be reversed by the methyltransferase
inhibitor zebularine (Hodge et al, 2005a), suggesting that
repression of SOD2 may occur at the level of epigenetic regulation.
In addition to understanding the relative mechanisms of SOD2
expression levels in cancer cells, little is known about the
consequences of reduced SOD2 on the signal transduction and
transcriptional processes that control cancer cell viability and
growth. Some data have emerged suggesting that levels of SOD2
have effects on AP-1 and NF-kB activities, in which overexpression
experiments diminish the activities of these two important
transcription factors (Kiningham and St Clair, 1997; Li et al,
1998a).
Here, using a series of pancreatic carcinoma cell lines, we show
that the relative expression patterns of SOD2 are inversely related
to the methylation density status of the sod2 promoter. Hyper-
methylation of CpG sites was rapidly reversed by the methyl-
transferase inhibitor zebularine, restoring SOD2 levels. The
epigenetic silencing of sod2 revealed a particular Achille’s heel of
pancreatic carcinoma cells with low SOD2, making the cells
particularly susceptible to the apoptotic effects of 2-methoxy-
estradiol (2ME2), an oxidative burst agent.
To examine the more global consequences of SOD2 expression
on the cellular processes of pancreatic carcinoma, we have
employed a gestalt approach of examining how SOD2 affects vital
processes of signal-transduction proteins, transcription factor
activation, and gene regulation. Using reverse-phase antibody
arrays for signal proteins, transcription factor arrays and gene
expression microarrays, we have identified some of the major
aspects in which SOD2 governs signal transduction and gene
expression in pancreatic carcinoma cells.
MATERIALS AND METHODS
Genomic DNA isolation, bisulphite modification, and PCR
amplification
Genomic DNA was isolated using Qiagen’s DNA isolation kit
(Qiagen). DNA was EcoRI digested, denatured with 0.3 M NaOH for
15min at 371C, and modified with 3.1 M sodium bisulphite and
0.5mM hydroquinone. Modified DNA was purified using the
QIAquick DNA extraction kit (Qiagen, Valencia, CA, USA) and
treated with 0.3 M NaOH for 15min at 371C to complete the
modification. Nested PCR was used to amplify the modified DNA
fragments. The first set of primers for the sod2 gene promoter
region (Genbank accession no. L34157) was 50-GtAtttTtAGGGG
[C/t]GGAt[C/t]GGAGGtAGGGtTT-30 (sense, nt 1896–1927) and
50-CCAaaCCC[a/G]aTaC[a/G]aCCACTaTC[a/G]CCATTaC-30 (anti-
sense, nt 2520–2490), and the second set of primers was 50-GGGt
[C/t]GTAttAAtTttA[C/t]GGGGGtAGGGGt-30 (sense, nt 1929–1958)
and 50-AaCCCCTTaCCCCTTaaaaC[a/G]TaACC[a/G]aaTCCC-30 (anti-
sense, nt 2468–2436), where lower case letters represent bisulphite-
converted nucleotides. PCR cycles were as follows: 951Cf o r3 0 s ,
followed by 35 cycles at 951Cf o r3 0s ,5 5 1C for 30s, 721Cf o r2m i n ,
and final extension at 721C for 10min. The amplified DNA fragment
of expected size was cloned into pCR4-TOPO TA cloning vector
(Invitrogen, Carlsbad, CA, USA). Ten individual clones for each cell
line were sequenced.
Construction of SOD2 expression and shRNA retroviruses
Adenoviral SOD2 construct (kind gift of JJ Cullen, University of
Iowa) was EcoRI digested and sod2 cDNA was cloned into the
retroviral vector pLZRS-BMN-eGFP containing an IRES and eGFP
cDNA. For overexpression experiments, the control was the empty
eGFP vector. The oligos used for shRNA knockdown of sod2 are as
follows: 50-GATCCCGGGGTTGGCTTGGTTTCAATATTCAAGAGA
TATTGAAACCAAGCCAACCCCTTTTTA-30 and 50-AGCTTAAAA
AGGGGTTGGCTTGGTTTCAATATCTCTTGAATATTGAAACCAA
GCCAACCCCGG-30. The oligos were annealed and cloned into the
BglII/HindIII sites of pRetroSuper (Brummelkamp et al, 2002).
Generation of stable cell lines with altered SOD2
expression levels
A bicistronic retrovirus carrying sod2 cDNA and eGFP or an empty
vector (control) was used to create the overexpression cell lines.
For knockdown of SOD2, the shSOD2-pRetroSuper or empty
pRetroSuper was used to infect pancreatic cell lines. In both
instances, the Phoenix Amphotropic cells (kind gift of Gary Nolan,
Stanford University) were transfected using FuGENE 6 (Roche
Diagnostics, Indianapolis, IN, USA), according to manufacturer’s
instructions. Two days following transfection, 3ml of viral
supernatant was used to infect 1–3 10
6 pancreatic cells. For
overexpression of SOD2, cells were flow sorted for high GFP
expression, whereas for shSOD2 and control cells were selected
with 1mgml
 1 puromycin 48h post infection. Expression of SOD2
was determined by western blot (anti-SOD2, ab16954; Abcam,
Cambridge, MA, USA).
Determination of superoxide dismutase activity in cell
lines
Superoxide dismutase activity was measured using Calbiochem’s
Superoxide Dismutase Assay Kit II according to manufacturer’s
directions. Briefly, 2 10
6 cells were sonicated in 20mM HEPES
buffer containing 1mM EGTA, 210mM mannitol, and 70mM
sucrose.
Ten microlitres of lysate was mixed with 200ml of radical
detector (tetrazolium salt) containing 1mM potassium cyanide to
inhibit Cu/Zn-SOD and 20ml xanthine oxidase. The reaction was
incubated at room temperature for 20min and read in a Genios
(Tecan, Palm Springs, CA, USA) plate reader at 450nm. One unit
of SOD activity is defined as the amount of enzyme needed to
exhibit 50% dismutation of the superoxide radical.
Measurement of proliferation by MTT assay
Cells were seeded in triplicate at 2 10
4 per well in a 96-well plate.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was performed in accordance with the manufacturer’s
instructions (Chemicon, Temecula, CA, USA). Briefly, following
addition of MTT, the cells were incubated at 371C for 2h. The
precipitate was resuspended in isopropanol containing 0.04 N
hydrochloric acid and read immediately using a Genios (Tecan)
plate reader at 570nm.
2-Methoxyestradiol treatment and comet assay
One million cells were treated with 3mM 2ME2 for 48h. DNA
damage was assessed using the CometAssay kit (Trevigen,
Gaithersburg, MD, USA). Briefly, 500–1000 cells were embedded
in 1.0% LMAagrose on a Cometslide and lysed (2.5 M sodium
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schloride, 100mM EDTA, pH 10, 1mM Tris base, 1% sodium lauryl
sarcosinate, and 1% Triton X-100). The slides were then
electrophoresed in alkaline electrophoresis solution (300mM
NaOH and 1mM EDTA) for 30min at 300mA. Cells were stained
with SYBR green and viewed by fluorescence microscopy. The
comet tail moment for 50 nuclei per treatment was measured using
ImageJ software (http://rsb.info.nih.gov/nih-image).
Oligonucleotide expression microarrays
Oligonucleotide microarrays were prepared by the National Cancer
Institute’s microarray core facility, using Operon’s Human version
3.0 oligo set (Operon Biotechnologies, Huntsville, AL, USA)
printed on UltraGAPS slides (Corning, Corning, NY, USA). This
set contains 34580 oligos, representing approximately 25000
unique genes. Total RNA (20mg) was labelled in a reverse
transcription (RT) reaction with an oligo-dT primer and either
Cy3-dUTP or Cy5-dUTP. Following the RT reaction, the RNA was
hydrolysed by incubation with NaOH. Probes were purified with a
Microcon YM-30 column (Millipore, Billerica, MA, USA). Micro-
arrays were prehybridised in 5  SSC, 0.1% SDS, and 1% BSA for
1h at 421C, washed in distilled water and then in 100% ethanol,
and air dried. Hybridisation of mixed Cy-3- and Cy-5-labelled
probes was performed in 50% formamide, 10  SSC, and 0.2% SDS
overnight at 421C. After hybridisation, slides were washed in
decreasing concentrations of SSC (2  SSCþ0.1% SDS, 1  SSC,
0.2  SSC). Arrays were scanned in a GenePix 4000B scanner and
analysed using GenePix Pro (Molecular Devices, Sunnyvale, CA,
USA). Data analysis was preformed using Cluster and TreeView,
offered by Michael B Eisen as freeware (http://rana.lbl.gov/
EisenSoftware.htm).
Reverse-phase protein arrays
Protein lysates were prepared for printing on reverse-phase
protein arrays (RPAs) by lysis of 10000 cells in T-PER (Pierce,
Rockford, IL, USA). Five two-fold serial dilutions were made from
each lysate. RPAs were printed as previously described (Paweletz
et al, 2001). Briefly, arrays were printed on nitrocellulose-coated
glass slides (FAST Slides, Whatman, Florham Park, NJ, USA) using
a GMS 417 arrayer (Affymetrix, Santa Clara, CA, USA). Each array
was incubated with primary antibody and detected using the
catalysed signal amplification system (Dako, Carpinteria, CA,
USA) and an Autostainer Universal Staining System (Dako). Slides
were blocked with I-block (Tropix, Bedford, MA, USA), incubated
with primary and secondary antibodies, streptavidin–biotin
complex, biotinyl tyramide, streptavidin-peroxidase, and deve-
loped with 3,30-diaminobenzidine tetrahydrochloride chromogen
with washing between all steps. Total protein was determined by
staining arrays with AuroDye Forte (GE Healthcare, Piscataway,
NJ, USA). The arrays were scanned with an Epson flat-bed scanner
(Epson, Long Beach, CA, USA) and quantitated using MicroVigene
with the dilution curve module (ViGene Tech, Carlisle, MA, USA).
For each sample, the slope of the regression line best fitting the
linear range of the dilution curve was used to determine relative
protein expression. All experimental values were normalised to
total protein.
DNA/protein arrays
Panomic’s DNA/protein Combo arrays containing 345 consensus
binding sites were hybridised according to manufacturer’s instruc-
tions. Briefly, nuclear protein was extracted using Panomic’s
Nuclear Protein extraction kit following manufacturer’s instruc-
tions. Fifteen micrograms of each protein lysate was used in the
binding reaction. Following clean-up, the probe was hybridised
at 451C overnight. Data were quantitated using ImageQuant
(Amersham Biosciences), and a binding site was considered to
be regulated only if it showed reciprocal regulation in the over-
expression and the shRNA cell lines.
RESULTS
Sod2 is methylated in some pancreatic cell lines leading to
decreased expression
Several reports have demonstrated decreased expression of SOD2
in pancreatic carcinoma (Su et al, 2002; Cullen et al, 2003) without
determining the underlying cause. To determine if decreased SOD2
expression could be the result of hypermethylation of the
promoter, we performed sodium bisulphite sequencing on four
pancreatic cell lines. We observed a high methylation density of
the sod2 promoter in MIA-PaCa2, intermediate methylation
densities in AsPc-1 and BxPc-3, and a low density in Capan-1
(Figure 1A). The degree of methylation was inversely correlated
with protein expression levels (Figure 1B).
Methylation of the sod2 promoter can be reversed with
zebularine resulting in re-expression of SOD2
To further substantiate the finding of hypermethylation of the sod2
promoter, we treated the three cell lines with zebularine (Driscoll
et al, 1991), a methyltransferase inhibitor (Zhou et al, 2002), and
determined methylation by sodium bisulphite sequencing
(Figure 1C). Treatment with zebularine nearly eliminated methyla-
tion of the sod2 promoter in both MIA-PaCa2 and AsPc-1. In
BxPc-3, methylation was minimally decreased and showed a more
limited pattern of demethylation with three regions showing a
greater extent of demethylation than the remaining areas. Capan-1
showed no significant changes in methylation densities. To
determine if the demethylation in response to zebularine treatment
lead to a corresponding increase in expression of SOD2, we
performed a western blot following zebularine treatment. Both
MIA-PaCa2 and AsPc-1 showed a significant increase in SOD2
protein levels (Figure 1D). There was no increase in SOD2
expression in both BxPc-3 and Capan-1 upon treatment with
zebularine (Figure 1D) consistent with the lesser extent of
demethylation.
SOD2 expression levels predict 2ME2 sensitivity that can
be ameliorated by introduction of SOD2
Pancreatic carcinomas have been shown to be sensitive to 2ME2
(Schumacher et al, 1999; Qanungo et al, 2002). The mechanism of
2ME2-induced apoptosis involves mitochondrial-dependent path-
ways (Qanungo et al, 2002) as well as ROS (Chauhan et al, 2003).
With diminished capacity to detoxify superoxide radicals, cells
with silenced SOD2 should exhibit higher sensitivity to 2ME2.
Using the four pancreatic carcinoma cell lines with variable SOD2
expression, we examined 2ME2 sensitivity in an MTT assay
(Figure 3A). Capan-1, which has the highest endogenous expres-
sion of SOD2, was the least sensitive to 2ME2, whereas MIA-PaCa2,
which has the lowest endogenous expression of SOD2, showed the
highest sensitivity to 2ME2 (Figure 2A). MIA-PaCa2 cells are
sensitive to 2ME2 (Schumacher et al, 1999), and the inhibition of
MIA-PaCa2 measured in the MTT assay is similar to the 42% of
apoptotic nuclei in MIA-PaCa2 following 2ME2 treatment for 48h
reported by Qanungo et al (2002). To test whether SOD2
expression itself could decrease sensitivity to 2ME2, we engineered
MIA-PaCa2 cells with altered levels of SOD2. We demonstrate that
these cell lines show both the expected level of expression and
enzymatic activity (Supplementary Figure 1). SOD2 overexpression
in MIA-PaCa2 leads to a slight reduction in sensitivity to 2ME2,
whereas SOD2 knockdown showed a slight increase in sensitivity
(Figure 2B).
SOD2 in pancreatic carcinoma cell lines
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sTreatment with 2ME2 leads to DNA damage and apoptosis
of pancreatic cell lines
Since 2ME2 induces ROS and PARP activation in pancreatic cell
lines (Qanungo et al, 2002), we tested whether or not 2ME2
induced DNA damage. Following treatment with 2ME2, there was
significant DNA damage induced in both MIA-PaCa2 and BxPc-3
(Figure 2C). MIA-PaCa2 showed a nearly three-fold increase in tail
length following treatment with 2ME2 as compared to control
(Figure 2C), whereas BxPc-3 showed an approximate two-fold
increase in tail length following 2ME2 treatment (Figure 2C). Both
AsPc-1 and Capan-1 showed little to no tailing following treatment
with 2ME2, indicating that 2ME2 did not lead to DNA damage in
these cell lines (Figure 2C and D). Capan-1 has the highest
expression of SOD2 and therefore the largest capacity to clear
superoxide radicals, which may account for the limited DNA
damage by 2ME2. While BxPc-3 shows a modest level of SOD2
expression, there was no tailing in response to 2ME2, which may
be due to increased expression of other ROS-scavenging enzymes
or better DNA repair mechanisms. While these results suggest that
SOD2 expression can reduce 2ME2-induced DNA damage, we
sought to directly determine if SOD2 expression alone could
ameliorate the effects of 2ME2. Therefore, we performed a comet
assay on MIA-PaCa2 with and without overexpression of SOD2.
The overexpression of SOD2 in MIA-PaCa2 substantially lessened
the extent of DNA damage incurred during treatment with 2ME2,
whereas treatment of the shSOD2 MIA-PaCa2 cells resulted in
increased damage (data not shown).
Gene expression changes result from the overexpression
and knockdown of SOD2
To address the changes in gene expression that result from SOD2
overexpression, we performed oligonucleotide arrays on MIA-
PaCa2 with SOD2 overexpression and knockdown. All genes
MIA-PaCa2
BxPc-3
AsPc-1
Capan-1
A
SOD2
Actin
M
I
A
-
P
a
C
a
2
B
x
P
C
-
3
A
s
P
c
-
1
C
a
p
a
n
-
1
B
M
I
A
-
P
a
C
a
2
B
x
P
c
-
3
A
s
P
c
-
1
Control
Control
ZEB
Control
ZEB
ZEB
D
SOD2
Actin
SOD2
Actin
M
I
A
-
P
a
C
a
2
B
x
P
c
-
3
A
s
P
c
-
1
C
a
p
a
n
-
1
SOD2
Actin
ZEB: –+
SOD2
Actin
C
C
a
p
a
n
-
1 Control
ZEB
+110 –205
+110 –205
Figure 1 The sod2 promoter is hypermethylated in some pancreatic carcinomas that is inversely correlated with protein levels. (A) The methylation
status of the sod2 promoter was examined by sodium bisulphite sequencing in four pancreatic carcinomas. All CpG dinucleotides are represented by either
an open circle (J) to indicate unmethylated cytosines or a filled circle (K) to indicate a methylated cytosine. (B) Protein levels of SOD2 were determined
by western blot. The level of SOD2 expression is inversely correlated with the extent of hypermethylation, with Capan-1 showing the lowest level of
methylation and the highest level of expression. Actin serves as a loading control. (C) Sodium bisulphite sequencing of three cell lines that showed
hypermethylation of the sod2 promoter following treatment with a methyltransferase inhibitor, zebularine, for 72h. (D) Protein expression levels of SOD2 in
pancreatic carcinoma lines following zebularine treatment.
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sshowing at least a two-fold change in expression in three of the
four overexpression experiments and an inverse change in the
knockdown experiment are shown in Figure 3A. There were 33
genes that showed a decrease in expression in the overexpression
experiments by the preceding criteria but no genes showing an
increase in expression by these same criteria. These genes are
involved in many different cellular processes, including calcium
homeostasis (fstl5, man1a1, efhd1, prkacb, and kcnip3), adhesion
(pscdbp and spon1), GTP metabolism (tbc1d14 and arhgap20), and
steroid metabolism (wwox and ugt2b7).
Signalling pathways showing altered activity with SOD2
expression
ROS has been shown to alter phosphorylation states of various
proteins, especially tyrosine phosphorylation. In order to investi-
gate the role of ROS on the phosphoproteome, we performed RPAs
with lysates from MIA-PaCa2 containing altered SOD2 levels.
Using these arrays, we identified a decrease in the phosphorylation
of VEGFR2 when SOD2 was overexpressed (Figure 3B). Other
reports have shown modification of VEGFR2 in response to
various ROS-inducing agents, including H2O2 (Gonzalez-Pacheco
et al, 2006), which is presumably increased in SOD2-deficient cell
lines. In contrast, there was no change in the phosphorylation
status of EGFR, STAT3, c-abl, or p-src detected using our RPAs
(Supplementary Table 1).
Changes in transcription factor binding as a result of SOD2
expression
In recent years, there has been considerable evidence that ROS
leads to changes in transcription factor binding. In order to
determine transcription factors that have altered DNA binding as a
result of SOD2 expression, we performed Panomic’s Protein/DNA
array that examines the binding activities of 354 transcription
factor binding sites. The experiment was conducted using nuclear
extracts from control MIA-PaCa2 cells, MIA-PaCa2 overexpressing
SOD2, as well as MIA-PaCa2 with SOD2 knockdown, and
transcription factors showing reciprocal changes in overexpression
and SOD2 knockdown are summarised in Table 1. Consistent with
the gene expression data, there were more transcription factors
identified that showed a decrease in binding upon SOD2
overexpression. Among those showing the greatest decrease in
binding activity were Brn-3, Myc/Mad, and TCF/LEF.
Identification of cognate binding sites for regulated
transcription factors in the promoters of regulated genes
With the identification of both transcription factors showing
altered DNA binding upon SOD2 expression and genes regulated
by SOD2, we sought to identify cognate binding sites for the
regulated transcription factors in the promoters of the regulated
genes. Of the 32 genes identified as being downregulated by SOD2
expression (Figure 3), promoter regions were found for 30 of them
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Figure 2 SOD2 protein levels modulate sensitivity to 2-methoxyestradiol and DNA damage. (A) Sensitivity to 2ME2 is inversely correlated with SOD2
expression levels. Following treatment with 3mM 2ME2 for 48h, an MTT assay was performed in triplicate. The number of viable cells following 2ME2
treatment is shown as a per cent of the number of viable of vehicle-treated cells. *Pp0.05, **Po0.001. A representative of three experiments is shown. (B)
Determination of sensitivity to 2ME2 was performed on MIA-PaCa2 cell lines with engineered SOD2 levels in triplicate by MTT. A representative of three
experiments is shown. The number of viable cells following 2ME2 treatment is shown as a per cent of the number of viable of vehicle-treated cells. Increased
expression of SOD2 results in decreased sensitivity, whereas decreased SOD2 levels result in increased sensitivity. *Pp0.05, **Po0.001. (C) DNA damage
was determined by comet assay following treatment with 2ME2. Four representative nuclei for each cell lines are shown. (D) The extent of DNA damage
following 2ME2 was determined by measuring the length of the tail moment of 50 nuclei. The fold-over-untreated mean tail moment length is shown where
an asterisk indicates a P-value p0.05.
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susing Genomatix’s Gene2Promoter database. The promoter
regions were scanned for binding sites of the downregulated
transcription factors listed in Table 2 using Genomatix’s
MatInspector. Of the 30 promoters searched, binding sites were
identified in 25 of them. Table 2 summarises these results.
DISCUSSION
The generation of ROS is a by-product of several cellular processes,
including electron transport (Cadenas, 1989). The elimination of
ROS is handled in the cell by several antioxidant enzymes,
including superoxide dismutases, which convert the superoxide
radical to H2O2. The H2O2 then gets converted into water and
molecular oxygen by peroxidases. The perturbation of any of these
processes can result in the build up of deleterious ROS in the cell.
ROS is implicated in the pathology of several cancers, including
pancreatic carcinoma (Cullen et al, 2003). Therefore, we sought to
better understand the role of ROS in pancreatic carcinoma. In
particular, we were interested in the effects that the manipulation
of SOD2 expression levels has in pancreatic carcinoma cell lines,
since they have decreased expression of SOD2 resulting in
increased proliferation rates.
One mechanism employed by cells for decreasing gene
expression levels is hypermethylation of the promoter. We have
recently shown that the sod2 promoter is hypermethylated in
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Figure 3 SOD2 expression in MIA-PaCa2 cells results in downregulation of several genes and phosphorylation of VEGFR2. (A) Oligonucleotide arrays
were performed on SOD2-engineered MIA-PaCa2 cell lines. All named genes showing at least a two-fold downregulation in two of three SOD2
overexpression experiments as well as an increase in the shSOD2 experiment are shown. (B) Reverse-phase protein arrays were performed to determine
differences in the phosphoproteome following manipulation of SOD2 protein levels. Phosphorylation of VEGFR2 is decreased in SOD2-overexpressed MIA-
PaCa2 cells. Total VEGFR2 expression remains unchanged between the vector-only control and the SOD2-overexpressed cells, with total protein shown as
the loading control.
Table 1 Transcription factors with modulated DNA binding activities in
SOD2-altered MIA-PaCa2 cells
Transcription factor Fold change SOD2 Fold change shSOD2
Transcription factors with decreased DNA binding upon infection with SOD2 retrovirus
Bm-3  10.7 1.2
C/EBP  7.5 3.6
NPAS2  6.1 1.9
Myc-Max  4.5 5.6
LyF-1  3.7 2.0
TCF/LEF  3.1 1.7
NRF-1  2.8 2.6
WT1  2.5 1.8
TCE  2.1 4.6
LR1  2.1 4.4
GATA-2  1.8 2.0
SP1  1.6 1.5
Transcription factors with increased DNA binding upon infection with SOD2 retrovirus
Pax-6 2.3  1.7
PCF 2.6  1.7
SOD2¼manganese superoxide dismutase. Transcription factors with altered binding
activity in response to engineered SOD2 expression levels in MIA-PaCa2 cells.
Transcription factor binding activity was determined by Panomic’s DNA/Protein
Combo array that profiles the binding activity of 390 transcription factors.
Transcription factors that showed reciprocal binding patterns with SOD2 over-
expression and knockdown are shown.
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smultiple myeloma (Hodge et al, 2005a), so we sought to determine
if hypermethylation may be an explanation for the decreased
expression of SOD2 observed in pancreatic carcinoma cell lines.
Through sodium bisulphite sequencing, we show that the
promoter of sod2 is hypermethylated in several cell lines (Figure 1),
including MIA-PaCa2. Furthermore, the expression of SOD2 was
increased following treatment of the cells with the methyltransfer-
ase inhibitor zebularine. The role of hypermethylation in the
silencing of sod2 in primary pancreatic carcinoma needs to be
determined, but our initial studies using the pancreatic carcinoma
cell lines indicate a possible role for hypermethylation.
Decreased expression of SOD2 would, theoretically, render the
cells less capable of eliminating ROS that may build up in the cell.
The decreased ability of cancer cells to eliminate ROS represents an
Achille’s heel that can be exploited to induce apoptosis of these cells.
Indeed, cells with lower expression of SOD2 are more sensitive to
the oxidative burst agent, 2ME2 (Figure 2). Therefore, for
carcinomas in which there is decreased SOD2 activity, regardless
of the mechanism, treatment with 2ME2 or other agents resulting in
oxidative bursts may represent a potential treatment option.
While lowered SOD2 expression in itself might present
treatment options for pancreatic carcinoma, the furthered under-
standing of the consequences of altered SOD2 expression
illuminates other mechanisms that could be involved in the
pathology of pancreatic cancer, suggesting further treatments. To
this end, we examined in an integrated proteomic and genomic
manner the consequences of SOD2 expression in MIA-PaCa2 cells
by both overexpression and knockdown of SOD2. Using this
approach, we have identified the genes that are regulated by SOD2
as well as the transcription factors whose binding activities are
altered in response to SOD2 expression. The genes identified in
Figure 3 function in diverse cellular processes, including calcium
binding, steroid metabolism, and cell adhesion. Calcium binding is
the most represented function according to Gene Ontology terms
and is affected by the expression of five out of the 32 genes shown
in Figure 3 (fstl5, man1a1, efhd1, prkacb, and kcnip3). The regula-
tion of calcium homeostasis is complex, but there is evidence that
ROS and calcium signalling pathways interact (reviewed by Yan
et al, 2006). The identification of the transcriptional regulation of
several genes involved in calcium regulation suggests that there
may be an even greater interplay between these two signalling
molecules and bears further investigation.
We identified the transcription factors in MIA-PaCa2 that show
altered binding activity in response to altered levels of SOD2
(Table 1). First, it is interesting to point out that nearly all of the
transcription factors identified show decreased binding. Second,
almost all of these transcription factors are also impacted by
calcium signalling. While the genes that are regulated by SOD2
expression could be regulated in some other manner, we sought to
determine if there was overlap in the transcription factors
identified as having SOD2-altered binding activities and the genes
identified as being SOD2-regulated. In order to do this, we first
identified the potential promoters of these genes using Genomatix’s
Gene2Promoter database. Once identified we used Genomatix’s
MatInspector to determine the transcription factor binding
modules. More than 80% of the promoters searched contained
binding sites for at least one of the regulated transcription factors.
The identification of binding sites for SOD2-regulated transcription
factors in the promoters of regulated genes (Table 2) strengthens
the use of computer analysis to begin to identify signalling
networks that may be at play in the cells studied.
We have shown that altered levels of SOD2 reveal a sensitivity to
oxidative stress created by 2ME2 treatment and result in
perturbations in the binding activities of several transcription
factors, decreased phosphorylation of VEGFR2, and the alteration
of the expression of several genes. The ability to determine both
the genomic and proteomic events that change as a result of SOD2
expression, and therefore the redox status of the cell, provides us
with a wealth of complex information. We have begun to
understand the molecular consequences of altered SOD2 activity
in pancreatic cancer and, furthermore, we have determined that
the lack of SOD2 expression may result in a therapeutic advantage.
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